CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Clinical Trial

Official title: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Status Active, not recruiting

Clinical Trial Summary

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com.

Clinical Trial Description

This is a multicenter, double-blind study in approximately 1400 participants, who will be randomized to receive subcutaneous (SC) injections of either eplontersen or placebo once every 4 weeks. Participants will also receive daily supplemental doses of the recommended daily allowance of vitamin A. ;

Related Conditions & MeSH terms

• Amyloidosis
• Cardiomyopathies
• Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

• NCT number: NCT04136171
• Study type: Interventional
• Source: Ionis Pharmaceuticals, Inc.
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 13, 2020
• Completion date: November 2025